Viridian Metals Highlights Copper-Rich Zones up to 4.15% Cu at Kraken Ahead of 2026 Drill Program

OTTAWA, Ontario, June 05, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) is advancing plans to target high-grade copper-rich zones identified within the Kraken magmatic sulphide system in Labrador, where drilling in 2024 intersected copper grades up to 4.15% Cu (see news release dated November 26, 2024). The Company's recently announced 50-hole drill program will provide the scale and flexibility required to systematically follow up on multiple copper-rich zones identified within the broader Kraken system.

GlobeNewsWire • Jun 5, 2026

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside chat on Wednesday, June 3, 2026, at 5:30pm ET in New York, NY Goldman Sachs 47th Annual Global Healthcare.

Business Wire • May 27, 2026

Viridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel Project

OTTAWA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- Viridian Metals (CSE: VRDN) (“Viridian” or the “Company”) will commence a minimum 50-hole drill program in early June at its Kraken Copper-Nickel Project in Labrador, aimed at defining the scope of copper-nickel sulphide mineralization traced over approximately 5 kilometres along the Main Zone. Previous drilling intersected mineralization at roughly 1-kilometre spacing, outlining the scale of the Main Zone discovery.

GlobeNewsWire • May 19, 2026

Viridian Metals Announces Flow-Through Private Placement, Warrant Extension and Date of Annual General and Special Meeting

OTTAWA, May 14, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) is pleased to announce that it has entered into a binding subscription agreement with Pavilion Flow- Through L.P. (2026) 1 (the “Investor”) in respect of a non-brokered private placement (the “Private Placement”) of flow-through units of the Company (the “Units”) at a price of $0.52 per Unit for aggregate gross proceeds to the Company of $750,000.

GlobeNewsWire • May 14, 2026

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced the pricing of its upsized underwritten public offering of $225.0 million aggregate principal amount of its 1.75% convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and its upsized underwritten publ.

Business Wire • May 7, 2026

Viridian eye disease drug benefits chronic patients in late-stage trial

Viridian Therapeutics said on Tuesday its experimental thyroid eye disease drug met the main goal of a late-stage trial in chronic patients.

Reuters • May 5, 2026

How This Amgen Rival, Up 30%, Plans To Shake Its Grip In Thyroid Eye Disease

Viridian Therapeutics unveiled solid results Tuesday for its experimental eye disease treatment, a potential rival to Amgen.

Investors Business Daily • May 5, 2026

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease Transcript

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease Transcript

Seeking Alpha • May 5, 2026

Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the first quarter ended March 31, 2026. “Our team continues its strong execution across our portfolio as we are launch ready ahead of veligrotug's PDUFA target date. We delivered positive topline data fro.

Business Wire • May 5, 2026

Viridian Shares Climb As Trial Data Reinforces Position In Thyroid Eye Disease Market

Viridian Therapeutics, Inc. (NASDAQ:VRDN) shares are up on Tuesday as the company announced positive topline results from its REVEAL-2 Phase 3 clinical trial for elegrobart, a treatment for chronic thyroid eye disease (TED).

Benzinga • May 5, 2026